The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.
The primary outcome measure of the trial is to compare progression-free survival after the administration of LOXO-305 as monotherapy compared with investigator choice.
The primary outcome measure of the trial is to evaluate progression-free survival after LOXO-305 monotherapy compared to investigator’s choice.
The researchers hypothesize that zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
The primary objective of this phase 2 trial is to evaluate the complete remission rate in patients with BTK inhibitor-refractory MCL with ixazomib and rituximab after 16 weeks.
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
Loxo Oncology is preparing to initiate the global, randomized, BRUIN MCL-321 superiority study in patients with Bruton tyrosine kinase inhibitor-naïve disease.
The plenary program will include talks on sickle cell disease, hematologic malignancies, resistance mechanisms, and treatment disparities.
